CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM088756
Első szerző:Losonczy Gergely (szemész)
Cím:Nagyfokú rövidlátás és időskori progresszív csapdisztrófia kialakulása az opszin gén 3-as exonjában található haplotípusok következtében / Losonczy Gergely, Orosz Orsolya, Vajas Attila, Takács Lili, Csutak Adrienne, Fodor Mariann, Kolozsvári Bence, Resch Miklós, Sényi Katalin, Lesch Balázs, Szabó Viktória, Berta András, Balogh István
Dátum:2020
Tárgyszavak:Orvostudományok Klinikai orvostudományok magyar nyelvű folyóiratközlemény hazai lapban
folyóiratcikk
Megjelenés:Szemészet. - 157 : 2 (2020), p. 156-163. -
További szerzők:Orosz Orsolya (1989-) (molekuláris biológus) Vajas Attila (1973-) (szemész) Takács Lili (1969-) (szemész) Csutak Adrienne (1971-) (szemész) Fodor Mariann (1975-) (szemész) Kolozsvári Bence Lajos (1977-) (szemész) Resch Miklós D. Sényi Katalin Lesch Balázs Szabó Viktória Berta András (1955-) (szemész, gyermekszemész) Balogh István (1972-) (molekuláris biológus, genetikus)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM081345
Első szerző:Losonczy Gergely (szemész)
Cím:Nem-szindrómás myopia vagy más betegség? / Losonczy Gergely, Orosz Orsolya, Vajas Attila, Takács Lili, Csutak Adrienne, Kolozsvári Bence, Fodor Mariann, Resch Miklós, Sényi Katalin, Lesch Balázs, Balogh István, Szabó Viktória, Berta András
Dátum:2017
Tárgyszavak:Orvostudományok Klinikai orvostudományok idézhető absztrakt
folyóiratcikk
Megjelenés:Szemészet. - 154 (2017), p. 50-51. -
További szerzők:Orosz Orsolya (1989-) (molekuláris biológus) Vajas Attila (1973-) (szemész) Takács Lili (1969-) (szemész) Csutak Adrienne (1971-) (szemész) Kolozsvári Bence Lajos (1977-) (szemész) Fodor Mariann (1975-) (szemész) Resch Miklós D. Sényi Katalin Lesch Balázs Balogh István (1972-) (molekuláris biológus, genetikus) Szabó Viktória Berta András (1955-) (szemész, gyermekszemész)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM068906
Első szerző:Orosz Orsolya (molekuláris biológus)
Cím:Myopia and Late-Onset Progressive Cone Dystrophy Associate to LVAVA/MVAVA Exon 3 Interchange Haplotypes of Opsin Genes on Chromosome X / Orsolya Orosz, István Rajta, Attila Vajas, Lili Takács, Adrienne Csutak, Mariann Fodor, Bence Kolozsvári, Miklós Resch, Katalin Sényi, Balázs Lesch, Viktória Szabó, András Berta, István Balogh, Gergely Losonczy
Dátum:2017
ISSN:0146-0404
Megjegyzések:Purpose: Rare interchange haplotypes in exon 3 of the OPN1LW and OPN1MW opsin genes cause X-linked myopia, color vision defect, and cone dysfunction. The severity of the disease varies on a broad scale from nonsyndromic high myopia to blue cone monochromatism. Here, we describe a new genotype?phenotype correlation attributed to rare exon 3 interchange haplotypes simultaneously present in the long- and middle-wavelength sensitive opsin genes (L- and M-opsin genes).Methods: A multigenerational family with X-linked high myopia and cone dystrophy was investigated.Results: Affected male patients had infantile onset myopia with normal visual acuity and color vision until their forties. Visual acuity decreased thereafter, along with the development of severe protan and deutan color vision defects. A mild decrease in electroretinography response of cone photoreceptors was detected in childhood, which further deteriorated in middle-aged patients. Rods were also affected, however, to a lesser extent than cones. Clinical exome sequencing identified the LVAVA and MVAVA toxic haplotypes in the OPN1LW and OPN1MW opsin genes, respectively.Conclusion: Here, we show that LVAVA haplotype of the OPN1LW gene and MVAVA haplotype of the OPN1MW gene cause apparently nonsyndromic high myopia in young patients but lead to progressive cone?rod dystrophy with deuteranopia and protanopia in middle-aged patients corresponding to a previously unknown disease course. To the best of our knowledge, this is the first report on the joint effect of these toxic haplotypes in the two opsin genes on chromosome X.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
X-linked high myopia
cone dystrophy
LVAVA
Megjelenés:Investigative Ophthalmology & Visual Science. - 58 : 3 (2017), p. 1834-1842. -
További szerzők:Rajta István (1970-) (fizikus) Vajas Attila (1973-) (szemész) Takács Lili (1969-) (szemész) Csutak Adrienne (1971-) (szemész) Fodor Mariann (1975-) (szemész) Kolozsvári Bence Lajos (1977-) (szemész) Resch Miklós D. Sényi Katalin Lesch Balázs Szabó Viktória Berta András (1955-) (szemész, gyermekszemész) Balogh István (1972-) (molekuláris biológus, genetikus) Losonczy Gergely (1977-) (szemész)
Pályázati támogatás:OTKA K109076
OTKA
GINOP-2.3.2-15-2016-00039
GINOP
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM117778
035-os BibID:(Scopus)85180756313 (WoS)001134783300003
Első szerző:Woo, Se Joon
Cím:Biosimilar SB15 versus reference aflibercept in neovascular age-related macular degeneration : 1-year and switching results of a phase 3 clinical trial / Woo Se Joon, Sadda SriniVas R., Bradvica Mario, Vajas Attila, Sagong Min, Ernest Jan, Studnička Jan, Veith Miroslav, Wylegala Edward, Patel Sunil, Yun Cheolmin, Orski Michal, Astakhov Sergei, Tóth-Molnár Edit, Csutak Adrienne, Enyedi Lajos, Choi Wooree, Oh Inkyung, Jang Hyerin
Dátum:2023
ISSN:2397-3269
Megjegyzések:BACKGROUND/AIMS: To evaluate efficacy, safety, pharmacokinetics (PK) and immunogenicity of SB15 versus reference aflibercept (AFL), and switching from AFL to SB15 in neovascular age-related macular degeneration (nAMD). DESIGN: Prospective, double-masked, randomised, phase 3 trial. METHODS: Participants with nAMD were randomised 1:1 to receive SB15 (N=224 participants) or AFL (N=225). At week 32, participants either continued on SB15 (SB15/SB15, N=219) or AFL (AFL/AFL, N=108), or switched from AFL to SB15 (AFL/SB15, N=111). This manuscript reports 1-year and switching results of secondary efficacy endpoints such as changes from baseline to week 56 in best-corrected visual acuity (BCVA), central subfield thickness (CST, from internal limiting membrane (ILM) to retinal pigment epithelium), and total retinal thickness (TRT, from ILM to Bruch's membrane). Additional endpoints included safety, PK and immunogenicity. RESULTS: Efficacy results were comparable between groups. The least squares mean (LSmean) change in BCVA from baseline to week 56 was 7.4 letters for SB15/SB15 and 7.0 letters for AFL/AFL (difference (95% CI)=0.4 (-2.5 to 3.2)). The LSmean changes from baseline to week 56 in CST and TRT were -119.2 ?m and -132.4 ?m for SB15/SB15 and -126.6 ?m and -136.3 ?m for AFL/AFL, respectively (CST: difference (95% CI)=7.4 ?m (-6.11 to 20.96); TRT: difference (95% CI)=3.9 ?m (-18.35 to 26.10)). Switched and non-switched participants showed similar LSmean changes in BCVA from baseline to week 56 (AFL/SB15, 7.9 letters vs AFL/AFL, 7.8 letters; difference (95% CI)=0.0 (-2.8 to 2.8)). Safety, PK and immunogenicity were comparable between groups. CONCLUSIONS: Efficacy, safety, PK and immunogenicity were comparable between SB15 and AFL and between switched and non-switched participants. ? Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
clinical trial
degeneration
macula
neovascularisation
Megjelenés:BMJ Open Ophthalmology. - 8 : 1 (2023), p. 1-10. -
További szerzők:Sadda, SriniVas R. Bradvica, Mario Vajas Attila (1973-) (szemész) Sagong, Min Ernest, Jan Studnicka, Jan Veith, Miroslav Wylegala, Edward Patel, Sunil Yun, Cheolmin Orski, Michal Astakhov, Sergei Tóth-Molnár Edit Csutak Adrienne (1971-) (szemész) Enyedi Lajos Choi, Wooree Oh, Inkyung Jang, Hyerin
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM113749
035-os BibID:(scopus)85165518293 (WOS)001003594000002
Első szerző:Woo, Se Joon
Cím:Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration / Woo Se Joon, Bradvica Mario, Vajas Attila, Sagong Min, Ernest Jan, Studnicka Jan, Veith Miroslav, Wylegala Edward, Patel Sunil, Yun Cheolmin, Orski Michal, Astakhov Sergei, Tóth-Molnár Edit, Csutak Adrienne, Enyedi Lajos, Kim Taehyung, Oh Inkyung, Jang Hyerin, Sadda SriniVas R.
Dátum:2023
ISSN:2168-6165 2168-6173
Megjegyzések:Importance - Aflibercept biosimilars can expand available treatment options in retinal diseases and have the potential to improve patient access to safe and effective therapy. Objective - To establish equivalence in efficacy and similarity in safety, pharmacokinetics, and immunogenicity of SB15 and reference aflibercept (AFL) in neovascular age-related macular degeneration (nAMD). Design, Setting, and Participants - This was a randomized double-masked parallel group phase 3 trial conducted at 56 centers in 10 countries from June 2020 to March 2022, including follow-up through 56 weeks. Of 549 screened participants, 449 participants 50 years and older with treatment-naive nAMD were included and randomly assigned to SB15 (n?=?224) or AFL (n?=?225). Key exclusion criteria included considerable scarring, fibrosis, atrophy, and hemorrhage. This report includes results up to the end of the parallel group period at week 32. Of the 449 randomized participants, 438 (97.6%) completed week 32 follow-up. Intervention - Participants were randomized 1:1 to receive 2 mg of SB15 or AFL every 4 weeks for the first 12 weeks (3 injections), followed by dosing every 8 weeks up to week 48, with final assessments at week 56. Main Outcomes and Measures - The primary end point was the change in best-corrected visual acuity (BCVA) from baseline to week 8 with predefined equivalence margins of ?3 letters to 3 letters. Other key end points were changes in BCVA and central subfield thickness up to week 32, safety, pharmacokinetics, and immunogenicity. Results - The mean (SD) age among the 449 included participants was 74.0 (8.1) years, and 250 participants (55.7%) were female. Baseline demographic characteristics and most disease characteristics were comparable between treatment groups. The least squares mean change in BCVA from baseline to week 8 in the SB15 group was equivalent to that in the AFL group (6.7 letters vs 6.6 letters, respectively; difference, 0.1 letters; 95% CI, ?1.3 to 1.4). Comparable efficacy between treatment groups was maintained up to week 32 (least squares mean change from baseline in BCVA: SB15, 7.6 letters vs AFL, 6.5 letters; least squares mean change from baseline in central subfield thickness: SB15, ?110.4 ?m vs AFL, ?115.7 ?m). No clinically relevant differences were observed in the incidence of treatment-emergent adverse events (TEAEs) (SB15, 107/224 [47.8%] vs AFL, 98/224 [43.8%]) and ocular TEAEs in the study eye (SB15, 41/224 [18.3%] vs AFL, 28/224 [12.5%]). The serum concentration profiles and cumulative incidences of overall antidrug antibody positive participants were comparable. Conclusions and Relevance - In this phase 3 randomized clinical trial, SB15 and AFL showed equivalent efficacy and comparable safety, pharmacokinetics, and immunogenicity in participants with nAMD.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:JAMA Ophthalmology. - 141 : 7 (2023), p. 668-676. -
További szerzők:Bradvica, Mario Vajas Attila (1973-) (szemész) Sagong, Min Ernest, Jan Studnicka, Jan Veith, Miroslav Wylegala, Edward Patel, Sunil Yun, Cheolmin Orski, Michal Astakhov, Sergei Tóth-Molnár Edit Csutak Adrienne (1971-) (szemész) Enyedi Lajos Kim, Taehyung Oh, Inkyung Jang, Hyerin Sadda, SriniVas R.
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1 
Corvina könyvtári katalógus v8.2.27 © 2023 Monguz kft. Minden jog fenntartva.